*Please cite this paper as:* Karimifar M. Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus. J Renal Inj Prev 2012;1(2):53-54. DOI: 10.12861/jrip.2012.19

Implication for health policy/practice/research/medical education: {#key1}
==================================================================

In cases of refractory thrombotic thrombocytopenic purpura use of rituximab is appropriate.

Systemic lupus erythematosus (SLE) is a systemic disease that can lead to involvement of many organs such as bone marrow, blood vessels, skin, heart, kidneys and central nervous system ([@R01]). Thrombotic thrombocytopenic purpura (TTP) is considered as a serious complication of SLE ([@R02]-[@R06]). The patient, described in this paper, was a 16 year-old girl who has recently diagnosed with SLE and treated with 5 mg prednisone, 200 mg hydroxychloroquine, and 1000 mg calcium daily. After a few months, a thrombocytopenia of 40,000 /µl was detected. She was treated with 60 mg daily prednisolone and 25 gram of daily IV-IgG for 5 consecutive days, and finally, due to lack of response to treatment, she has been referred to Al-Zahra Medical Center. In clinical examination of peripheral blood, smear schistocyte of 8% and thrombocytopenia of 10,000/µl was detected. The value of serum LDH and hemoglobin were 1200 IU/ml and 9 g/dl, respectively. Following diagnosis of TTP, the patient underwent plasmapheresis. The patient with TTP were treated with daily plasmapheresis for 8 days replacing with 2 liters of fresh frozen plasma. In the meantime platelets reached to 140,000/µl and LDH regressed to normal value. One day after cessation of plasmapheresis, the platelet count felt to 60,000/µl, and in the second day it reached to 1000/µl. Also, hemoglobin dropped to 4g/dl and LDH raised to 1800 mg/dl. At this stage, two units of packed red blood cells infused and six additional plasmapheresis sessions were performed. However, there was not a significant improvement of platelet count. After ruling out of hepatitis B, 500 mg of rituximab once weakly and 125 mg methylprednisolone were intravenously infused, for three consecutive days. Then, 200 mg oral cyclosporine was started. Moreover plasmapheresis, continued again for 5 days and then stopped. Seven days later, the same dose of rituximab was repeated. At this time the platelet count was 105,000/µl, hemoglobin = 9 g/dl and LDH was normal and patient was discharged with 60 mg oral prednisolone, 200 mg cyclosporine and 200 mg hydroxychloroquine. Rituximab was repeated for two consecutive weeks after discharge. Finally, after four consecutive weeks of starting rituximab therapy, the platelet count was 260,000/µl, the hemoglobin reached to 11g/dl and, and the LDH remained normal.

Conclusion {#s2}
==========

In cases of refractory thrombotic thrombocytopenic purpura use of rituximab is appropriate.
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